Results 91 to 100 of about 61,558 (234)

Patient‐derived surgical samples reveal the cellular and molecular signatures of glioblastoma infiltration in distinct radiological zones

open access: yesBrain Pathology, EarlyView.
Integrated histological and transcriptional profiling of the glioblastoma periphery reveals clinically relevant tumor infiltration beyond MRI‐defined boundaries. MRI‐guided biopsies from contrast‐enhancing (CE), non‐contrast‐enhancing (nCE), edema (E), and radiologically normal (N) regions demonstrate that nCE areas frequently retain neoplastic and ...
Olaya de Dios   +18 more
wiley   +1 more source

Mammalian target of rapamycin inhibition protects glioma cells from temozolomide-induced cell death

open access: yesCell Death Discovery
Glioblastoma is an incurable brain tumor with a median survival below two years. Trials investigating targeted therapy with inhibitors of the kinase mTOR have produced ambiguous results.
Benedikt Sauer   +9 more
doaj   +1 more source

Complement receptor C3aR marks heterogeneous tumor‐associated macrophage states associated with improved survival in IDH‐wildtype glioblastoma

open access: yesBrain Pathology, EarlyView.
C3aR expression in IDH‐wildtype glioblastoma is predominantly associated with the myeloid/macrophage compartment and heterogeneous macrophage states. C3aR‐high tumors are enriched among MGMT promoter‐methylated tumors and show improved overall survival, although the prognostic association requires independent validation.
Marion Imara   +9 more
wiley   +1 more source

PTEN homozygous deletion is a negative prognostic factor in tumor treating fields‐treated glioblastoma, IDH wildtype patients

open access: yesBrain Pathology, EarlyView.
In a molecularly confirmed cohort of 64 newly diagnosed, TTFields‐treated glioblastomas, IDH‐wildtype, homozygous PTEN deletion was associated with markedly shorter overall survival (368 vs. 603 days) and remained an independent adverse prognostic factor.
Jakob Nückles   +15 more
wiley   +1 more source

Application progress of temozolomide in clinical tumor chemotherapy

open access: yesChinese Journal of Contemporary Neurology and Neurosurgery, 2013
Temozolomide is an imidazotetrazine derivative of the alkylating agent, which is used to treat central nervous system tumors, especially malignant brain gliomas. It is a milestone in brain giloma chemotherapy. Recently, some researchers used temozolomide
Cheng ZHONG, Bin WANG, Sheng-qing LV
doaj  

Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes

open access: yesBrain Pathology, EarlyView.
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu   +12 more
wiley   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

open access: yesBritish Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka   +3 more
wiley   +1 more source

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways

open access: yesJournal of Translational Medicine
Background In the fight against GBM, drug repurposing emerges as a viable and time-saving approach to explore new treatment options. Chlorpromazine, an old antipsychotic medication, has recently arisen as a promising candidate for repositioning in GBM ...
Paola Matarrese   +5 more
doaj   +1 more source

Genomic Evolution and Immune Contexture With Therapeutic Relevance in Pancreatic Neuroendocrine Neoplasms

open access: yesCancer Science, EarlyView.
Lineage‐dependent immunogenomic landscapes and biologically informed therapy in pancreatic neuroendocrine neoplasms. Pancreatic neuroendocrine neoplasms display lineage‐dependent immunogenomic landscapes, in which genomic alterations, epigenetic states, antigen‐presentation status, immune‐cell infiltration, and suppressive microenvironments co‐evolve ...
Yohei Tabe   +5 more
wiley   +1 more source

Pleiotropic Roles of FBXO11 in Tumorigenesis: Implications for Targeted Therapy

open access: yesCancer Science, EarlyView.
This complex comprises of scaffold CUL1, SKP1, RBX1 and FBXO11 receptor. The substrate is phosphorylated by specific kinase enzyme and recognized by the substrate recognition domain. FBXO11 targets numerous substrates for ubiquitination and degradation, FBXO11 substrates mainly include Snail, ZEB1, p53, BCL6, CDT2, CIITA, Cdc25a, hnRNPA2B1, SAMD1 and ...
Yuqi Zhang   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy